William R. Martin

William R. Martin

Auto-generated profile, based on publicly available information

William R. Martin

Cleveland State University 2121 Euclid Avenue

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2020 in Cell Discovery
Verified
Journal Article
Open access
PDF file
YZYadi Zhou
Yadi Zhou
YHYuan Hou
Yuan Hou
JSJiayu Shen
Jiayu Shen
YHYin Huang
Yin Huang
WMWilliam Martin
William Martin
FCFeixiong Cheng
Feixiong Cheng
Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2. Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV–host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the “Complementary Exposure” pattern: the targets of the drugs both hit the HCoV–host subnetwork, but target separate neighborhoods in the human interactome network. In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting 2019-nCoV/SARS-CoV-2.

8 February 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
FCFeixiong Cheng
Feixiong Cheng
JZJunfei Zhao
Junfei Zhao
YWYang Wang
Yang Wang
WLweiqiang lu
weiqiang lu
ZLZehui Liu
Zehui Liu
JLJoseph Loscalzo
Joseph Loscalzo

9 September 2020 in Journal of Proteome Research
Verified
Journal Article
Closed access
WMWilliam R. Martin
William R. Martin
FCFeixiong Cheng
Feixiong Cheng

10 March 2021 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
WMWilliam R. Martin
William R. Martin
FCFeixiong Cheng
Feixiong Cheng
The ongoing global health crisis caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus which leads to Coronavirus Disease 2019 (COVID-19) has impacted not only the health of people everywhere, but the economy in nations across the world. While vaccine candidates and therapeutics are currently undergoing clinical trials, there is a lack of proven effective treatments or cures for COVID-19. In this study, we have presented a synergistic computational platform, including molecular dynamics simulations and immunoinformatics techniques, to rationally design a multi-epitope vaccine candidate for COVID-19. This platform combines epitopes across Linear B Lymphocytes (LBL), Cytotoxic T Lymphocytes (CTL) and Helper T Lymphocytes (HTL) derived from both mutant and wild-type spike glycoproteins from SARS-CoV-2 with diverse protein conformations. In addition, this vaccine construct also takes the considerable glycan shield of the spike glycoprotein into account, which protects it from immune response. We have identified a vaccine candidate (a 35.9 kDa protein), named COVCCF, which is composed of 5 LBL, 6 HTL, and 6 CTL epitopes from the spike glycoprotein of SARS-CoV-2. Using multi-dose immune simulations, COVCCF induces elevated levels of immunoglobulin activity (IgM, IgG1, IgG2), and induces strong responses from B lymphocytes, CD4 T-helper lymphocytes, and CD8 T-cytotoxic lymphocytes. COVCCF induces cytokines important to innate immunity, including IFN-γ, IL4, and IL10. Additionally, COVCCF has ideal pharmacokinetic properties and low immune-related toxicities. In summary, this study provides a powerful, computational vaccine design platform for rapid development of vaccine candidates (including COVCCF) for effective prevention of COVID-19. Communicated by Ramaswamy H. Sarma

7 October 2021 in Current Opinion in Structural Biology
Verified
Journal Article
Closed access
WMWilliam Martin
William Martin
GSGloria Sheynkman
Gloria Sheynkman
FLFelice C. Lightstone
Felice C. Lightstone
RNRuth Nussinov
Ruth Nussinov
FCFeixiong Cheng
Feixiong Cheng